therapeutic strategy based on pharmacogenomic principles and targeted therapies to alter the natural history of disease early in its course, thereby preventing adverse outcomes and improving health. Amazingly, a shift to this paradigm is already happening, led by forward-thinking physicians, scientists, and health-care providers. The results of new studies go beyond a 'statistically significant association' to clarify the underlying disease mechanisms and define principles that can be applied in predictive ways to improve patients' lives.
How can CTG be a leader in emerging health care and especially personalized medicine? First, CTG is open access so that anyone can read and interact with new advances immediately. Second, CTG offers rapid publication of highquality papers, without waiting for openings in monthly journal volumes. Third, the complexity of the questions we face in translational science and precision medicine requires international collaborations to solve. Many of the brightest minds in the world remain in countries with limited resources and where English is not the native language. Thus, researcher investment into the publication cost of a high-quality, open-access journal that publishes studies written in simple, clear English remains the best way to make important work accessible, impactful, and more frequently cited. It also addresses the issue of when publicly funded research should become publicly available. Fourth, CTG is committed to publishing expert perspectives on the field, either as "Translational Medicine: Bench to Bedside," "Gut Instincts," or as more lengthy narrative reviews, in order to continually update physicians about important advances. Through this approach, we hope CTG will address the 10 well-defined hurdles impeding implementation of precision medicine 2 for complex disorders in general, and digestive diseases in particular.
CTG, as a society journal, belongs to the American College of Gastroenterology, and it serves broader goals in publishing than the focused area that I intend to champion. Indeed, CTG should also serve as a venue for early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. Thus, as an openaccess sister journal to the American Journal of Gastroenterology, CTG should serve a complementary role in disseminating new knowledge and ideas to an educated and proactive community of specialty physicians. This balance of design, goals, and vision will be maintained by the appointment of 1 two outstanding Associate Editors, Ashwin Ananthakrishnan, MD, MPH, and Amit Singal, MD, MS, with special expertise in luminal disorders and IBD, and in liver disorders and hepatocellular carcinoma, respectively.
Yogi Berra noted, "It's tough to make predictions, especially about the future." One can easily predict that health-care delivery will change drastically in the near future, especially in the United States. We trust that the nature and quality of works published in CTG will provide insight and guidance for practicing medicine in smarter ways, so that everyone will benefit. Our commitment is to provide outstanding service to the field of gastroenterology and hepatology and forge the way into the future.
